Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Insuline glulisine · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Insuline glulisine | DRUG | - |
Inclusion Criteria: * type I diabetes mellitus (onset of diabetes under the age of 40), * an HbA1c range of \>6.5 - \<11%, * and on multiple injection regimen (more than 1 year of continuous insulin treatment), * body mass index \<35. Exclusion Criteria: * Active proliferative diabetic retinopath...
Insuline glulisine is used to treat Diabetes Mellitus, Type 1. It is a rapid-acting insulin therapy studied in combination with Lantus (insulin glargine) in adult patients with type 1 diabetes. Sanofi is the developer of this asset.
Insuline glulisine is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor behind the clinical development program for this rapid-acting insulin analog in type 1 diabetes.
Insuline glulisine is in Phase 3 clinical development for Diabetes Mellitus, Type 1. The program includes two completed Phase 3 trials with a combined enrollment of 202 patients. No active trials are currently listed for this asset.
Insuline glulisine has been studied in two completed Phase 3 trials. NCT00546702, titled Glulisine + Lantus in Type I Patients, enrolled 142 patients in Russia. NCT00545337, with the same title, enrolled 60 patients in Ukraine. Both trials required participants to be at least 18 years old.
Both Phase 3 trials evaluated insuline glulisine in combination with Lantus in patients with type 1 diabetes. The studies were uncontrolled, meaning they did not use a randomized or double-blind design. NCT00546702 enrolled 142 patients in Russia, and NCT00545337 enrolled 60 patients in Ukraine.